Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
This page aggregates historical and ongoing news coverage related to the ticker symbol LIFE, which historically represented aTyr Pharma, Inc. on the Nasdaq Capital Market. aTyr describes itself as a clinical stage biotechnology company developing first-in-class medicines from a proprietary tRNA synthetase platform, with a focus on fibrosis and inflammation. Company news has highlighted scientific progress, clinical milestones, and corporate developments tied to this strategy.
Readers can expect news items covering aTyr’s lead therapeutic candidate, efzofitimod, a biologic immunomodulator in clinical development for interstitial lung disease. Press releases have described key events such as Phase 3 EFZO-FIT™ trial updates in pulmonary sarcoidosis, Phase 2 EFZO-CONNECT™ enrollment in systemic sclerosis-related interstitial lung disease, and independent data and safety monitoring board reviews recommending continuation of the EFZO-FIT™ study without modification. Scientific conference presentations, including posters detailing efzofitimod’s mechanism of action through neuropilin-2 and its effects on myeloid cells, also feature prominently.
In addition to clinical and scientific updates, the news stream includes corporate communications such as quarterly results, pipeline summaries, and the announcement of the Nasdaq ticker change from LIFE to ATYR. These releases provide context on how aTyr is advancing its tRNA synthetase-based discovery platform, managing its clinical portfolio, and communicating with the investment community.
For investors, researchers, and clinicians following aTyr, the LIFE news archive offers a structured view of how the company’s programs have evolved over time. By reviewing these items, users can trace the development of efzofitimod in interstitial lung disease, observe the company’s engagement with scientific and investor conferences, and understand the rationale behind the transition from the LIFE ticker to ATYR. Bookmark this page to access a consolidated history of company announcements associated with the LIFE symbol.
aTyr Pharma (Nasdaq: LIFE) has appointed Dr. Sara Zaknoen to its Board of Directors. Dr. Zaknoen, with extensive experience in pharmaceutical drug development, previously served as Chief Medical Officer at several biotech firms. This strategic appointment comes as aTyr prepares for the readout of its proof-of-concept study for ATYR1923 in pulmonary sarcoidosis by Q3 2021. The company is also advancing its oncology candidate ATYR2810, targeting Neuropilin-2. Dr. Zaknoen's background is expected to enhance aTyr's clinical development efforts.
aTyr Pharma announced findings related to ATYR2810, a Neuropilin-2 (NRP2) antibody, presented at the Virtual Keystone Symposia on Cancer Stem Cells. The research demonstrates that ATYR2810 effectively blocks the NRP2/VEGF signaling axis, enhancing chemotherapy sensitivity in triple-negative breast cancer (TNBC) models. Notably, ATYR2810 downregulates cancer stem cell and epithelial-mesenchymal transition markers in TNBC samples. These findings underscore the potential of ATYR2810 as a therapeutic candidate in treating aggressive tumors.
aTyr Pharma reported Q1 2021 results, highlighting progress in its clinical trials and research initiatives. The company anticipates data from a Phase 1b/2a trial of ATYR1923 in pulmonary sarcoidosis by Q3 2021. Preclinical data for ATYR2810 showed anti-tumor effects in triple-negative breast cancer and non-small cell lung cancer. As of March 31, 2021, aTyr had $50.6 million in cash and equivalents. The company raised $25.2 million through offerings during Q1 2021 and expects ongoing increases in expenses due to heightened R&D activities.
aTyr Pharma (Nasdaq: LIFE) announced that its Hong Kong subsidiary, Pangu BioPharma, achieved key milestones in a two-year, $750,000 grant from the Hong Kong Government’s Innovation and Technology Commission. The project, in collaboration with the Hong Kong University of Science and Technology, focuses on developing bispecific antibodies targeting Neuropilin-2 (NRP2) for diseases like cancer. The initial year included establishing a research team and implementing a novel antibody discovery approach, yielding promising candidates for therapeutic assays.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research, on May 11, 2021. Dr. Nangle has been with aTyr since 2007, previously serving as Senior Director and Head of Research. With over 20 years in tRNA synthetase research, she is well-positioned to lead ongoing projects, including the development of ATYR1923, aimed at treating inflammatory lung diseases. aTyr focuses on innovative medicines derived from novel biological pathways, boasting an IP portfolio of over 300 therapeutically relevant proteins.
aTyr Pharma (Nasdaq: LIFE) will report its first quarter 2021 financial results on May 13, 2021, after market close. The management will host a conference call and webcast at 5:00 pm EDT to discuss the results and provide a corporate update. The company specializes in innovative medicines based on biological pathways, focusing on ATYR1923, a candidate for inflammatory lung diseases. For more details, visit aTyr Pharma's website.
aTyr Pharma (Nasdaq: LIFE) and the Foundation for Sarcoidosis Research (FSR) announced a virtual town hall on April 27, 2021, focusing on steroids and sarcoidosis. The event will tackle treatment options and strategies for patients suffering from this chronic condition. A panel of experts, including aTyr's CEO Sanjay S. Shukla, will discuss current treatments and the need for new options like ATYR1923. Approximately 150,000 to 200,000 Americans are affected by pulmonary sarcoidosis, making this discussion timely during Sarcoidosis Awareness Month.
aTyr Pharma, Inc. (Nasdaq: LIFE) has signed a contract with Lonza for the production of ATYR2810, a monoclonal antibody targeting Neuropilin-2 (NRP2), which is in preclinical development for cancer. This partnership will utilize Lonza’s Ibex® Design to manufacture cGMP material for ATYR2810, supporting both drug substance and product for toxicological studies and early clinical development. The agreement underlines aTyr's focus on advancing ATYR2810 for aggressive tumors linked to NRP2, aiming for eventual clinical trials.
aTyr Pharma announces promising findings for ATYR2810, a monoclonal antibody targeting Neuropilin-2, at the 2021 AACR Annual Meeting. The preclinical studies showed that ATYR2810 significantly inhibited tumor growth in non-small cell lung cancer models when used alone and enhanced the effects of chemotherapy in triple-negative breast cancer models. The research, conducted in collaboration with UMass Medical School, suggests that ATYR2810 may overcome tumor resistance and provide a new therapeutic avenue for treating aggressive cancers. The company aims to advance ATYR2810 to clinical trials.
aTyr Pharma (Nasdaq: LIFE) appointed Andrea Wilson as a patient advisor, focusing on strategies for the clinical program of ATYR1923 in pulmonary sarcoidosis. Ms. Wilson, a sarcoidosis patient and the co-founder of the Foundation for Sarcoidosis Research, aims to leverage her advocacy experience to support patient strategies. ATYR1923 is currently in a Phase 1b/2a trial, targeting inflammatory lung diseases, particularly pulmonary sarcoidosis, affecting approximately 150,000 to 200,000 Americans.